Screener
Viridian Therapeutics, Inc. VRDN Free cash flow
Free cash flow at other companies
Other financials
Where this comes from
Calculated from Viridian Therapeutics, Inc.’s reported figures.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
FAQ
- What is Viridian Therapeutics, Inc.'s free cash flow?
- Viridian Therapeutics, Inc. (VRDN) reported free cash flow of -$106.63M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s free cash flow changed year-over-year?
- Viridian Therapeutics, Inc.'s free cash flow decreased by 41.4% year-over-year, from -$75.42M to -$106.63M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s free cash flow?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s free cash flow has grown at a 49.8% compound annual growth rate (CAGR), from -$54.92M to -$276.89M.
- What does free cash flow mean?
- Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.
Ask your AI about Viridian Therapeutics, Inc.'s free cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude